The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.

El Sayed, Ahmed Nasr; Moustafa, Hosna; Abd El Metal, Gamal; Tawakol, Ahmed

doi:10.21608/ejchem.2022.156309.6763

The impact of hormonal status on 18FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT.

Document Type : Review Articles

Authors

¹ Nuclear Medicine Department, Kasr Al-Ainy Center of Clinical Oncology &amp;amp; Nuclear Medicine, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt

² Oncology and Nuclear Medicine Department (NEMROCK), Kasr-El-Ainy Hospital, Cairo University, Egypt

³ Medical Oncology department At Maadi Armed Forces Medical Compound Kasr-El-Ainy Hospital, Cairo University, Egypt

⁴ Oncology and Nuclear Medicine Department (NEMROCK), Kasr -El-Ainy Hospital, Cairo University, Egypt

10.21608/ejchem.2022.156309.6763

Abstract

Introduction

FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment.

The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes.

Material and Methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and Basal like subtype (8 patients). All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end of therapy.

Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions (49 in LNs, 24 in lung, 8 in liver; while 39 in bone). Metastatic lesions in PET/CT were 98 lesions (46 in LNs, 22 in lung and 8 in liver and 22 in bone). During follow up after therapy, the majority of luminal A group showed complete response to therapy to therapy in PET/CT scan PET/CT scan. Also, luminal B+ subgroup showed partial response. While most of basal-like subgroup showed progressive disease.

Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular subtypes. The mean SUV max showed relation to the different molecular subtypes.

Keywords

Main Subjects